CXCL1, CXCL10 and CXCL12 Chemokines are Variously Expressed in Acute Myeloid Leukemia Patients Prior and Post Bone Marrow Transplantation

Document Type : Research Articles

Authors

1 Department of Hematology and Blood Banking, Kerman University of Medical Sciences, Kerman, Iran.

2 Molecular Medicine Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.

3 Department of Hematology and Medical Laboratory Sciences, Iranshahr University of Medical Sciences, Iranshahr, Iran.

4 Pistachio safety Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.

5 Department of Laboratory Sciences, Khomein University of Medical Sciences, Khomein, Iran.

6 Department of Internal Medicine, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.

7 Department of Pediatrics, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.

Abstract

Aim: The chemokine-receptor axes play parts in development of leukemia, CXCL1, CXCL10 and CXCL12 are involved in immune responses. Thus, we have examined the serum levels of these chemokines in parallel with their related cognate receptors (CXCR1, CXCR3 and CXCR4) in AML (acute myeloid leukemia) patients prior and post BMT (bone marrow transplantation) therapy. Main methods: Clinical specimens were collected from 46 AML patients (23 M1 and 23 M3 subtypes) before/after BMT. CXCL1, CXCL10 and CXCL12 concentrations were determined by ELISA. The mRNA levels of the related receptors were detected by QRT_PCR. Data were analyzed by T-test, χ2 and ANOVA statistical methods in SPSS software version 18. A difference was regarded significant if P value < 0.05. Key findings: Our results indicated that the elevated levels of CXCL12 in AML patients were remained unchanged after transplantation.  The CXCL10 concentration was decreased in patients. All studied chemokines were elevated in BMT patients with history of 9 times PLT transfusion. In patients who received BMT from siblings CXCL1 and CXCL10 have been elevated, whereby they were compared to patients who received BMT from parents while CXCL12 sustained unchanged in groups. Serum measures of CXCL1 and CXCL10 were induced in acute and chronic GVHD patients in compare to these without GVHD. Significance: According to the results, it can be concluded that these chemokines play fundamental parts in pathogenesis of both AML and BMT. It is worthy to note that chemokines could be used as diagnostic markers alongside with possible promising therapeutic targets.

Keywords

Main Subjects


Volume 22, Issue 10
October 2021
Pages 3377-3384
  • Receive Date: 24 May 2021
  • Revise Date: 03 August 2021
  • Accept Date: 24 October 2021
  • First Publish Date: 24 October 2021